StemRIM

StemRIM P/TBV

The Price to Tangible Book Value (P/TBV) of StemRIM (4599.T) as of Nov 2, 2026 is 3.26. In the previous year, Price to Tangible Book Value (P/TBV) was 2.55 — a change of 27.98% (higher).

P/TBV

3.26

YoY

27.98%

Last updated:

Price to Tangible Book Value (P/TBV) of StemRIM is 2026 3.26 . Price to Tangible Book Value (P/TBV) of StemRIM was 2025 2.55 . It decreases by 27.98% higher compared to the previous year.

The StemRIM P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2019
7.18 JPY
Jan 1, 2020
1.72 JPY
Jan 1, 2021
1.74 JPY
Jan 1, 2022
1.98 JPY
Jan 1, 2023
1.80 JPY
Jan 1, 2024
2.09 JPY
Jan 1, 2025
2.55 JPY
Jan 1, 2026
3.26 JPY
The StemRIM P/TBV history
YEARP/TBVYoY
3.26+27.98%
2.55+21.61%
2.09+16.62%
1.80-9.31%
1.98+13.73%
1.74+1.44%
1.72-76.09%
7.18-27.84%
9.94-47.06%
18.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemRIM Stock analysis

What does StemRIM do? StemRIM, Inc. develops and researches regeneration-inducing medicine based on a new action mechanism to promote functional regeneration and healing of damaged biological tissue. The company's main product is stem cell regeneration-inducing medicine, which delivers therapeutic effects similar to regenerative medicine without requiring living cells or tissues. StemRIM's primary customers are medical institutions and healthcare providers seeking advanced treatment options for tissue repair and regeneration. The company generates revenue through the sale of its stem cell regeneration-inducing medicine to these healthcare segments. StemRIM focuses on research and development of medicines that can restore lost function in biological tissue caused by injury or illness. The firm's product line centers around its stem cell regeneration-inducing medicine, which eliminates the need for using living cells in treatment. This innovative approach targets medical professionals and institutions looking for efficient regenerative solutions. StemRIM's business model relies on selling its patented medicine to healthcare providers for clinical applications. The company's revenue streams come from the commercialization of its stem cell regeneration-inducing medicine, which is designed to provide regenerative therapy without cell-based treatments. StemRIM's target market includes hospitals and medical facilities that require advanced regenerative treatments for patients with tissue damage. The firm's research and development efforts are centered on creating medicines that can promote healing through a novel mechanism, differentiating their product from traditional regenerative medicine approaches. StemRIM is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemRIM stock

Price to Tangible Book Value (P/TBV) of StemRIM is 3.26 in 2026.

Price to Tangible Book Value (P/TBV) of StemRIM changed from 2.55 to 3.26, representing a 27.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) StemRIM since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s StemRIM with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — StemRIM

All Key Metrics — StemRIM